Goldman Sachs initiated coverage of Arcutis Biotherapeutics (ARQT) with a Neutral rating and $18 price target The company’s lead asset Zoryve has a favorable profile and is preferred by many dermatologists over generic topicals and steroids, but its growth going forward may be challenged, the analyst tells investors in a research note. The firm awaits clarity on Zoryve before recommending Arcutis shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARQT:
- Arcutis Biotherapeutics Completes Promising Psoriasis Treatment Study
- Arcutis Biotherapeutics assumed with an Overweight at Morgan Stanley
- Arcutis announces ZORYVE cream receives strong recommendation from AAD
- Arcutis Biotherapeutics Approves Key Proposals at Annual Meeting
- Arcutis Biotherapeutics enrolls first child in INTEGUMENT-INFANT